The University of Southampton
University of Southampton Institutional Repository

Letter. Ceftriaxone drug alert: no longer for first line use in meningococcal sepsis.

Letter. Ceftriaxone drug alert: no longer for first line use in meningococcal sepsis.
Letter. Ceftriaxone drug alert: no longer for first line use in meningococcal sepsis.
Although UK and international high income country practice has been to recommend ceftriaxone or cefotaxime as first line therapy for the initial treatment of paediatric sepsis, the US FDA has issued an alert1 that has led to changes in the US label for ceftriaxone.2 Due to concerns regarding the potential for calcium chelation in vivo, ceftriaxone must no longer be administered within 48 h of the completion of infusions of calcium-containing solutions, including parenteral nutrition, regardless of whether the drugs are administered by different infusion catheters.1 2 In the UK, the current drug safety bulletin3 states that ceftriaxone must not be given simultaneously with calcium-containing infusions.
We would therefore like to update the antibiotic recommendation made in our meningococcal therapy guideline update published in the April 2007 issue of ADC4 as follows: "Cefotaxime should be used as the first line antibiotic in meningococcal sepsis due to the high incidence of calcium replacement requirement in severe disease. However, ceftriaxone may still be considered as first line therapy in children with clinical meningitis, and for continuation of sepsis therapy after the acute phase when calcium infusions are no longer required. Where children are admitted for observation following cefotaxime for suspected sepsis and are subsequently assessed as being well enough for discharge on ambulatory intravenous antibiotics, the antibiotic may be changed to ceftriaxone (where the once/day dose regimen may be of benefit) and the first dose administered 8 hours following the last dose of cefotaxime given, assuming no calcium containing infusions have been used or are planned". The Meningitis Research Foundation will be making appropriate changes to their educational literature.
0003-9888
184-185
Faust, S.N .
f97df780-9f9b-418e-b349-7adf63e150c1
Pollard, A.J .
f9934b6a-e702-4557-80ff-ca0e0852351f
Nadel, S.
3504007b-b6c5-4716-a0a4-a4c5461753ba
Ninis, N.
1ce069aa-f919-48a5-849f-18fe1f022c26
Levin, M.
3668029d-82f9-422c-8a69-42ccae2e88bf
Faust, S.N .
f97df780-9f9b-418e-b349-7adf63e150c1
Pollard, A.J .
f9934b6a-e702-4557-80ff-ca0e0852351f
Nadel, S.
3504007b-b6c5-4716-a0a4-a4c5461753ba
Ninis, N.
1ce069aa-f919-48a5-849f-18fe1f022c26
Levin, M.
3668029d-82f9-422c-8a69-42ccae2e88bf

Faust, S.N ., Pollard, A.J ., Nadel, S., Ninis, N. and Levin, M. (2008) Letter. Ceftriaxone drug alert: no longer for first line use in meningococcal sepsis. Archives of Disease in Childhood, 93 (2), 184-185.

Record type: Article

Abstract

Although UK and international high income country practice has been to recommend ceftriaxone or cefotaxime as first line therapy for the initial treatment of paediatric sepsis, the US FDA has issued an alert1 that has led to changes in the US label for ceftriaxone.2 Due to concerns regarding the potential for calcium chelation in vivo, ceftriaxone must no longer be administered within 48 h of the completion of infusions of calcium-containing solutions, including parenteral nutrition, regardless of whether the drugs are administered by different infusion catheters.1 2 In the UK, the current drug safety bulletin3 states that ceftriaxone must not be given simultaneously with calcium-containing infusions.
We would therefore like to update the antibiotic recommendation made in our meningococcal therapy guideline update published in the April 2007 issue of ADC4 as follows: "Cefotaxime should be used as the first line antibiotic in meningococcal sepsis due to the high incidence of calcium replacement requirement in severe disease. However, ceftriaxone may still be considered as first line therapy in children with clinical meningitis, and for continuation of sepsis therapy after the acute phase when calcium infusions are no longer required. Where children are admitted for observation following cefotaxime for suspected sepsis and are subsequently assessed as being well enough for discharge on ambulatory intravenous antibiotics, the antibiotic may be changed to ceftriaxone (where the once/day dose regimen may be of benefit) and the first dose administered 8 hours following the last dose of cefotaxime given, assuming no calcium containing infusions have been used or are planned". The Meningitis Research Foundation will be making appropriate changes to their educational literature.

This record has no associated files available for download.

More information

Published date: February 2008

Identifiers

Local EPrints ID: 59294
URI: http://eprints.soton.ac.uk/id/eprint/59294
ISSN: 0003-9888
PURE UUID: da26bdc4-be75-4c39-ba57-73215d70d057
ORCID for S.N . Faust: ORCID iD orcid.org/0000-0003-3410-7642

Catalogue record

Date deposited: 03 Sep 2008
Last modified: 09 Jan 2022 03:21

Export record

Contributors

Author: S.N . Faust ORCID iD
Author: A.J . Pollard
Author: S. Nadel
Author: N. Ninis
Author: M. Levin

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×